Glen L Xiong1, Kevin Prybol, Stephen H Boyle, Russell Hall, Robert D Streilein, David C Steffens, Ranga Krishnan, Joseph G Rogers, Christopher M O'Connor, Wei Jiang. 1. From the Department of Psychiatry & Behavioral Sciences (Xiong), University of California at Davis, Davis, California; Departments of Community and Family Medicine (Prybol), Psychiatry & Behavioral Sciences (Boyle, Krishnan, Jiang), Immunology and Dermatology (Hall, Streilein), and Internal Medicine, Division of Cardiology (Rogers, O'Connor, Jiang), Duke University Medical Center, Durham, North Carolina; and Department of Psychiatry (Steffens), University of Connecticut Health Center, Farmington, Connecticut.
Abstract
BACKGROUND: Major depressive disorder (MDD) and chronic heart failure (CHF) have in common heightening states of inflammation, manifested by elevated inflammation markers such as C-reactive protein. This study compared inflammatory biomarker profiles in patients with CHF and MDD to those without MDD. METHODS: The study recruited patients admitted to inpatient care for acute heart failure exacerbations, after psychiatric diagnostic interview. Patients with Beck Depression Inventory (BDI) scores lower than 10 and with no history of depression served as the nondepressed reference group (n = 25). MDD severity was defined as follows: mild (BDI 10-15; n = 48), moderate (BDI 16-23; n = 51), and severe (BDI ≥ 24; n = 33). A Bio-Plex assay measured 18 inflammation markers. Ordinal logistic models were used to examine the association of MDD severity and biomarker levels. RESULTS: Adjusting for age, sex, statin use, body mass index, left ventricular ejection fraction, tobacco use, and New York Heart Association class, the MDD overall group variable was significantly associated with elevated interleukin (IL)-2 (p = .019), IL-4 (p = .020), IL-6 (p = .026), interferon-γ (p = .010), monocyte chemoattractant protein 1 (p = .002), macrophage inflammatory protein 1β (p = .003), and tumor necrosis factor α (p = .004). MDD severity subgroups had a greater probability of elevated IL-6, IL-8, interferon-γ, monocyte chemoattractant protein 1, macrophage inflammatory protein 1β, and tumor necrosis factor α compared with nondepressed group. The nondepressed group had greater probability of elevated IL-17 (p < .001) and IL-1β (p < .01). CONCLUSIONS: MDD in patients with CHF was associated with altered inflammation marker levels compared with patients with CHF who had no depression. Whether effective depression treatment will normalize the altered inflammation marker levels requires further study. TRIAL REGISTRATION: ClinicalTrials.gov NCT00078286.
BACKGROUND: Major depressive disorder (MDD) and chronic heart failure (CHF) have in common heightening states of inflammation, manifested by elevated inflammation markers such as C-reactive protein. This study compared inflammatory biomarker profiles in patients with CHF and MDD to those without MDD. METHODS: The study recruited patients admitted to inpatient care for acute heart failure exacerbations, after psychiatric diagnostic interview. Patients with Beck Depression Inventory (BDI) scores lower than 10 and with no history of depression served as the nondepressed reference group (n = 25). MDD severity was defined as follows: mild (BDI 10-15; n = 48), moderate (BDI 16-23; n = 51), and severe (BDI ≥ 24; n = 33). A Bio-Plex assay measured 18 inflammation markers. Ordinal logistic models were used to examine the association of MDD severity and biomarker levels. RESULTS: Adjusting for age, sex, statin use, body mass index, left ventricular ejection fraction, tobacco use, and New York Heart Association class, the MDD overall group variable was significantly associated with elevated interleukin (IL)-2 (p = .019), IL-4 (p = .020), IL-6 (p = .026), interferon-γ (p = .010), monocyte chemoattractant protein 1 (p = .002), macrophage inflammatory protein 1β (p = .003), and tumor necrosis factor α (p = .004). MDD severity subgroups had a greater probability of elevated IL-6, IL-8, interferon-γ, monocyte chemoattractant protein 1, macrophage inflammatory protein 1β, and tumor necrosis factor α compared with nondepressed group. The nondepressed group had greater probability of elevated IL-17 (p < .001) and IL-1β (p < .01). CONCLUSIONS:MDD in patients with CHF was associated with altered inflammation marker levels compared with patients with CHF who had no depression. Whether effective depression treatment will normalize the altered inflammation marker levels requires further study. TRIAL REGISTRATION: ClinicalTrials.gov NCT00078286.
Authors: Gregory E Miller; Cinnamon A Stetler; Robert M Carney; Kenneth E Freedland; William A Banks Journal: Am J Cardiol Date: 2002-12-15 Impact factor: 2.778
Authors: Wei Jiang; Harry Oken; Mona Fiuzat; Linda K Shaw; Carolyn Martsberger; Maragatha Kuchibhatla; Rima Kaddurah-Daouk; David C Steffens; Rebecca Baillie; Michael Cuffe; Ranga Krishnan; Christopher O'Connor Journal: J Cardiovasc Transl Res Date: 2011-11-01 Impact factor: 4.132
Authors: W Jiang; J Alexander; E Christopher; M Kuchibhatla; L H Gaulden; M S Cuffe; M A Blazing; C Davenport; R M Califf; R R Krishnan; C M O'Connor Journal: Arch Intern Med Date: 2001 Aug 13-27
Authors: Willem J Kop; John S Gottdiener; Catherine M Tangen; Linda P Fried; Mary Ann McBurnie; Jeremy Walston; Anne Newman; Calvin Hirsch; Russell P Tracy Journal: Am J Cardiol Date: 2002-02-15 Impact factor: 2.778
Authors: Russell P Hall; Keith M Benbenisty; Clinzo Mickle; Fumiko Takeuchi; Robert D Streilein Journal: J Invest Dermatol Date: 2007-06-28 Impact factor: 8.551
Authors: Christopher M Celano; Ana C Villegas; Ariana M Albanese; Hanna K Gaggin; Jeff C Huffman Journal: Harv Rev Psychiatry Date: 2018 Jul/Aug Impact factor: 3.732
Authors: Christopher M Celano; Eleanor E Beale; Scott R Beach; Arianna M Belcher; Laura Suarez; Shweta R Motiwala; Parul U Gandhi; Hanna Gaggin; James L Januzzi; Brian C Healy; Jeff C Huffman Journal: Psychosom Med Date: 2017-04 Impact factor: 4.312
Authors: Debra K Moser; Cynthia Arslanian-Engoren; Martha J Biddle; Misook Lee Chung; Rebecca L Dekker; Muna H Hammash; Gia Mudd-Martin; Abdullah S Alhurani; Terry A Lennie Journal: Curr Cardiol Rep Date: 2016-12 Impact factor: 2.931
Authors: Kenneth E Freedland; Brian C Steinmeyer; Robert M Carney; Eugene H Rubin; Michael W Rich Journal: Health Psychol Date: 2019-05 Impact factor: 4.267
Authors: Kenneth E Freedland; Michael J Hesseler; Robert M Carney; Brian C Steinmeyer; Judith A Skala; Victor G Dávila-Román; Michael W Rich Journal: Psychosom Med Date: 2016-10 Impact factor: 4.312
Authors: Annica J Rasmusson; Maike Gallwitz; Bardia Soltanabadi; Diana M Ciuculete; Jonas Mengel-From; Kaare Christensen; Marianne Nygaard; Mette Soerensen; Adrian E Boström; Robert Fredriksson; Eva Freyhult; Jessica Mwinyi; Darina Czamara; Elisabeth B Binder; Helgi B Schiöth; Janet L Cunningham Journal: Transl Psychiatry Date: 2021-06-24 Impact factor: 6.222